<div id="readability-page-1"><div>(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: ---------- FTSE 100 ---------- Barclays cuts Diageo price target to 2,470 (2,490) pence - 'overweight' ---------- Bernstein cuts Diageo price target to 2,420 (2,550) pence - 'outperform' ---------- Jefferies cuts Diageo price target to 2,300 (2,400) pence - 'buy' ---------- RBC cuts Diageo price target to 2,000 (2,200) pence - 'sector perform' ---------- Deutsche Bank Research cuts Diageo price target to 1,840 (1,915) pence - 'hold' ---------- JPMorgan raises M&amp;G price target to 315 (305) pence - 'overweight' ---------- Jefferies cuts Hikma Pharmaceuticals price target to 2,360 (2,575) pence - 'buy' ---------- Barclays cuts Hikma Pharmaceuticals target to 2,100 (2,300) pence - 'equal weight' ---------- JPMorgan raises GSK price target to 1,500 (1,400) pence - 'underweight' ---------- Goldman Sachs raises AstraZeneca price target to 15,504 (15,163) pence - 'buy' ---------- JPMorgan raises Auto Trader target to 770 (765) pence - 'underweight' ---------- Goldman Sachs cuts Weir Group to 'neutral' (buy) - price target 2,900 (2,570) pence ---------- UBS raises Weir Group price target to 3,450 (3,200) pence - 'buy' ---------- Deutsche Bank Research raises IMI price target to 2,900 (2,625) pence - 'buy' ---------- UBS raises IMI price target to 2,550 (2,500) pence - 'neutral' ---------- Kepler Cheuvreux cuts Sainsbury to 'reduce' (hold) - price target 336 (295) pence ---------- Goldman Sachs raises Sainsbury price target to 400 (355) pence - 'buy' ---------- UBS raises Sainsbury price target to 365 (330) pence - 'buy' ---------- Goldman Sachs raises National Grid price target to 1,254 (1,244) pence - 'buy' ---------- Barclays raises National Grid price target to 1,210 (1,200) pence - 'overweight' ---------- Deutsche Bank Research raises Standard Chartered price target to 1,700 (1,200) pence - 'hold' ---------- FTSE 250 ---------- Deutsche Bank Research raises RS Group to 'buy' (hold) - price target 760 pence ---------- RBC cuts Breedon price target to 525 (575) pence - 'outperform' ---------- Jefferies raises Ceres Power price target to 460 (205) pence - 'buy' ---------- Barclays cuts ITV price target to 75 (85) pence - 'equal weight' ---------- Bernstein cuts ITV price target to 74 (75) pence - 'market-perform' ---------- Goldman Sachs raises Lancashire Holdings price target to 763 (736) pence - 'buy' ---------- Barclays raises Watches of Switzerland target to 510 (425) pence - 'overweight' ---------- UBS raises Watches of Switzerland price target to 440 (415) pence - 'neutral' ---------- Investec reinitiates Avon Technologies with 'buy' - price target 2,300 pence ---------- Deutsche Bank Research cuts Derwent London price target to 2,100 (2,400) pence - 'hold' ---------- UBS raises British Land to 'buy' (neutral) - price target 435 (410) pence ---------- SMALL CAP ---------- UBS raises Ryanair price target to 32.55 (29.60) Eur - 'buy' ---------- RBC cuts Sabre Insurance to 'sector perform' (outperform) - price target 135 (170) pence ---------- Jefferies cuts S4 Capital price target to 40 (45) pence - 'buy' ---------- Barclays cuts S4 Capital price target to 23 (24) pence - 'equal weight' ---------- Goldman Sachs cuts Wise price target to 1,500 (1,550) pence - 'buy' ---------- Barclays cuts Wise price target to 1,250 (1,300) pence - 'overweight' ---------- Deutsche Bank Research cuts Wise price target to 940 (990) pence - 'hold' ---------- Deutsche Bank Research raises Frontier Developments price target to 580 (390) pence - 'hold' ---------- Comments and questions to newsroom@alliancenews.comCopyright 2025 Alliance News Ltd. All Rights Reserved.</div></div>

WEIR

Goldman Sachs has downgraded Weir Group to 'neutral' with a price target of 2,900 pence, down from 2,570 pence. Conversely, UBS has upgraded British Land to 'buy' with a price target of 435 pence, increased from 410 pence. Other notable changes include various price target adjustments for Diageo, Hikma Pharmaceuticals, and AstraZeneca by multiple analysts.

Goldman Sachs cuts Weir; UBS ups British Land